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A B S T R A C T
Background
Over the past ten years laparoscopy has become an increasingly common approach for the surgical removal of early stage ovarian
tumours. There remains uncertainty about the value of this intervention. This review has been undertaken to assess the available
evidence of the benefits and harms of laparoscopic surgery for the management of early stage ovarian cancer compared to laparotomy.
Objectives
To evaluate the benefits and harms of laparoscopy in the surgical treatment of FIGO stage I ovarian cancer (stages Ia, Ib and Ic) when
compared with laparotomy.
Search methods
Trials were identified by searching the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled
Trials (CENTRAL), The Cochrane Library Issue 2, 2007, MEDLINE (January 1990 to November 2007), EMBASE (1990 to November
2007), LILACS (1990 to November 2007), BIOLOGICAL ABSTRACTS (1990 to November 2007) and Cancerlit (1990 to November
2007). We also searched our own publication archives, based on prospective handsearching of relevant journals from November 2007.
Reference lists of identified studies, gynaecological cancer handbooks and conference abstract were also scanned.
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Selection criteria
Studies including patients with histologically proven stage I ovarian cancer according to the International Federation of Gynaecology
and Obstetrics (FIGO).
Studies comparing laparoscopic surgery with laparotomy for early stage ovarian cancer were only available from 1990. It was anticipated
that a very small number of randomised controlled trials (RCTs) were conducted studying the management of early stage ovarian cancer.
Therefore, non-randomised comparative studies, cohort studies and case-controls studies, but not studies with historical controls, were
also considered.
Data collection and analysis
Data extraction was performed independently by five review authors (LRM, DDR, MIR, MCB and MIE) who assessed study quality
and quality of extracted data. Extracted data included trial characteristics, characteristics of the study participants, interventions and
outcomes. The quality of non RCTs was assessed using appropriate quality evaluations tools from the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) and from the Newcastle-Ottawa tool for observational studies (NOS).
Main results
No RCTs were identified. Three observational studies were identified.
Authors’ conclusions
This review has found no evidence to help quantify the value of laparoscopy for the management of early stage ovarian cancer as routine
clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer
Controversial discussion has arisen among endoscopists and oncologists about the laparoscopic management of early stage ovarian
tumours. This systematic review found no evidence to help quantify the value of laparoscopy for the management of early stage ovarian
cancer in clinical practice.
B A C K G R O U N D
Malignant ovarian neoplasms are responsible for four per cent
of all cancer affecting women and are the second most common
cause of death from gynaecological cancer and the fourth most
common cause of death from all types of cancer affecting women
(Yancik 1993). Diagnosis of early stage ovarian cancer (limited to
the ovaries) is rare and is mainly made by accidental discovery at
the time of routine ultrasonography or during laparoscopy. The in-
cidence of managing an unexpected ovarian cancer by laparoscopy
is 6.5 in 1000 women with an adnexal mass (Wenzl 1996).
Most cancers of the ovary are epithelial. The most common his-
tologic subtype is serous (40 to 70% of all types); endometrioid
tumours are the second most common, (20% to 25% of all cases).
Mucinous epithelial tumours are rarer, comprising 5% to 20% of
all cases (Kosary 1994).
Borderline ovarian tumours constitute approximately 5.9% of low
malignant potential (Medeiros 2005).
The diagnosis of borderline ovarian tumours is more difficult due
to variations in the histopathologic criteria used among different
countries for the differential diagnosis between borderline and
malignant lesions (Burger 2000). Stromal and germ cell tumours
comprise 1.1% to 1.7% of all cases of malignant ovarian tumours
(Medeiros 2005).
The prognosis of all ovarian tumours is independently affected
by the following factors: stage of cancer at diagnosis, histological
subtype, tumoral grading and the volume of residual disease after
surgery (Benedet 2000). Current standard treatment for patients
with early stage ovarian cancer is a laparotomy with a longitudinal
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median incision to allow the required surgical staging (Benedet
2000; Hand 1993; Kosary 1994). The primary tumour, if limited
to the ovary, must be examined to look for capsular rupture (
Benedet 2000). There is evidence that the overall survival rate can
be higher when the transformed cells are confined to the ovaries
(Crayford 2000).
For patients with borderline tumours with obvious limited disease
(stage Ia) and normal examination of the opposite ovary conserva-
tive therapy can be administered when there is a desire to maintain
fertility (Benedet 2000; Vinatier 1996). For patients with FIGO
stage Ia, Ib or Ic, the proposed surgical treatment includes total
hysterectomy and bilateral salpingo-oophorectomy and all obvi-
ous sites of tumour must be removed (Benedet 2000; Vinatier
1996). Furthermore, the omentum, pelvic and para-aortic lymph
nodes should be removed for histological examination in order to
obtain accurate staging (Benedet 2000; Vinatier 1996).
Recently two parallel RCTs, the International Collaborative Ovar-
ian Neoplasm 1 (ICON1) (Trimbos 2003) and the Adjuvant Che-
motherapy in Ovarian Neoplasm (ACTION) (Trimbos 2004) in
early-stage ovarian cancer compared platinum-based adjuvant che-
motherapy with observation following surgery. They showed that
adjuvant chemotherapy may provide further benefits for women
with stage I ovarian cancer. ICON1 reported an improvement
in overall survival of 8% and in recurrence-free survival of 11%
in patients treated with adjuvant platinum-based chemotherapy
compared with observation only (Trimbos 2003).
However, ACTION also showed that adjuvant chemotherapy sig-
nificantly improved the overall and the disease-free survival only
in inadequately staged patients (Trimbos 2004), though this was
a post hoc sub group analysis. In addition, a systematic review led
by Elit et al. found similar results, especially when patients were
not submitted for lymphadenectomy as part of the surgical staging
(Elit 2004). Therefore in the patients who had undergone optimal
surgical staging, adjuvant chemotherapy may have had no effect
on the prognosis (Trimbos 2004; Vergote 2003). Many physicians
believe that the best policy for the treatment of patients with early
stage ovarian cancer is to make efforts to achieve optimal surgical
staging and to save adjuvant chemotherapy for those patients in
whom optimal staging is not feasible (Trimbos 2004). However,
there are no RCTs addressing optimal staging or surgery.
Laparoscopy has been restricted to patients with pre-operative ev-
idence of a benign diagnosis (Vergote 2004). The inappropriate
treatment of a malignant condition by endoscopy is associated
with worse prognosis (Lehner 1998). Rupture of an ovarian malig-
nant tumour should be avoided at the time of surgery for an early
stage ovarian cancer (Vergote 2004). Some endoscopic procedures
are performed using CO2 laser techniques, and this is considered
by some authors to increase the risk of activating cell enzymes
which may lead to mitosis and an increase in the production of
tumour growth factors. If the duration of laparoscopic surgery is
prolonged there may also occur mechanical or chemical damage of
the mesothelium which, in some cases of malignancy may be inad-
vertently treated as a benign lesion, increasing the risks of metas-
tases in the abdominal cavity (Greene 1995; Volz 1999). How-
ever, reports addressing the selective use of laparoscopic techniques
in the management of malignant gynaecologic disease have been
published with increasing frequency (Chi 1999; Dottino 1999;
Kadar 1997; Vinatier 1996), although it still remains controversial
whether laparoscopy is a good choice for the management early
stage ovarian cancer (Vergote 2004).
It is not yet established whether laparoscopy is as good as or bet-
ter than the conventional surgical approach for the treatment of
ovarian tumours which are assumed to be malignant. Given the
limited evidence from randomised trials in this area of surgery, and
the concerns that have arisen over quality, an objective analysis
of the literature requires evaluation of both randomised and non-
randomised studies. We performed a systematic review to com-
pare laparoscopy with laparotomy as surgical approaches for the
treatment of early stage ovarian cancer.
O B J E C T I V E S
To evaluate the benefits and harms of laparoscopy in the surgical
treatment of FIGO stage I ovarian cancer (stages Ia, Ib and Ic)
when compared with laparotomy.
The following issues were addressed in this review:
• Is laparoscopy (intervention group) effective in improving
overall survival (OS) (compared with laparotomy (control group)
in patients with FIGO stage I ovarian cancer?
• Is laparoscopy (intervention group) effective in improving
progression free survival (PFS) compared with laparotomy
(control group) in patients with FIGO stage I ovarian cancer?
• Does primary laparoscopy result in less surgical
complications than laparotomy (control group) in patients with
FIGO stage I ovarian cancer?
• Does primary laparoscopy (intervention group) result in
more local recurrence (port site) than laparotomy (control group)
in midline incision in patients with FIGO stage I ovarian cancer?
• Does primary laparoscopy (intervention group) result in
more distant recurrence than laparotomy (control group) in
patients with FIGO Stage I ovarian cancer?
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• Does primary laparoscopy (intervention group) result more
tumour spillage at the time of surgery than laparotomy (control
group) in patients with FIGO stage I ovarian cancer?
• Does primary laparoscopy (intervention group) result in
less cost than laparotomy (control group) in patients with FIGO
stage I ovarian cancer?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Inclusion criteria
Studies of patients with histologically proven stage I ovarian can-
cer according to the International Federation of Gynaecology and
Obstetrics (FIGO) were included.
Studies comparing laparoscopic surgery with laparotomy for early
stage ovarian cancer were only available from 1990.
It was anticipated that a very small number of RCTs would have
been conducted analysing patients with early stage ovarian cancer.
Therefore, non-randomised comparative studies, cohort studies
and case-controls studies, but not studies with historical controls,
were also considered.
Exclusion criteria
All studies regarding patients with early stage ovarian cancer who
desired to remain fertile, treated by conservative surgery (unilateral
salpingo-oophorectomy).
All studies where ovarian cancer was inadequately staged.
Types of participants
Patients with early stage ovarian cancer was included, i.e. patients
with disease confined to the ovaries, no lymph node involvement
or distant metastases.
The International Federation of Gynaecology and Obstetrics
(FIGO) distinguishes patients with stage I ovarian cancer as fol-
lows (Scully 1999):
Stage Ia: unilateral tumours
Stage Ib: bilateral tumours
Stage Ic: identifies tumour spillage, tumour capsular penetration,
positive peritoneal cytology
No lymph node involvement or distant metastases
Whenever possible the results were stratified by: histological sub-
groups of ovarian cancer.
Histological sub grouping for malignant ovarian tumours were
considered whenever possible (Scully 1999):
(1) Surface epithelial-stromal tumours:
(a) serous type (borderline and malignant)
(b) mucinous type (borderline and malignant)
(c) endometrial type
(2) Germ cell tumours:
(a) teratoma (immature and monodermal types)
(b) dysgerminoma
(c) yolk sac tumour
(d) embryonal carcinoma
(e) carcinoid tumours
(3) Sex cord-stromal tumours:
(a) granulosa-stromal cell tumours
(b) sertoli-stromal cell tumours (androblastoma)
(c) sex cord tumour with annular tubules
(d) gynandroblastoma
(e) unclassified sex cord-stromal tumour
(f ) steroid (lipid) cell tumour
Types of interventions
Two surgical approaches used for the management of FIGO stage
I ovarian cancer were compared: laparoscopy (intervention group)
and laparotomy (control group).
Types of outcome measures
Primary outcomes
(1) Survival at five years
(2) Progression free-survival (PFS) at five years
Secondary outcomes
(1) Tumour spillage at the time of surgery.




(a) Surgical complications (immediate and delayed):
(i) injury (to the bladder, urether, vascular, small bowel and colon
injuries);





(vii) rate of conversion to laparotomy.
(b) Systemic complications:
(i) chest infection;
(ii) deep venous thrombosis;
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(d) Recovery from surgery: length of hospital stay and re-admission
rates.
Search methods for identification of studies
Electronic searches
Searches was conducted to identify all published and unpublished
RCTs and non RCTs comparing laparoscopy and laparotomy for
early stage ovarian cancer. The search strategies identified studies
in all languages and, when necessary, non English language papers
were translated so that they could be fully assessed for potential
inclusion in the review.
Trials were identified by searching the Cochrane Gynaecological
Cancer Group Trials Register, Cochrane Central Register of Con-
trolled Trials (CENTRAL), The Cochrane Library Issue 2, 2007,
MEDLINE (January 1990 to November 2007), EMBASE (1990
to November 2007), LILACS (1990 to November 2007), BIO-
LOGICAL ABSTRACTS (1990 to November 2007) and Can-
cerlit (1990 to November 2007).
MEDLINE was searched using the following strategies:
1. Randomized controlled trial. pt.
2. Controlled clinical trial.pt
3. Randomizes controlled trials/
4. random allocation/




9. exp clinical trials/
10. (clin$ adj25 trial$).ti,ab,sh.







17. (animal not human).sh
18. 16 not 17
19. comparative study.sh
20. exp evaluation studies
21. follow up studies.sh
22. prospective studies
23. (control$ or prospectiv$).mp or volunter$.ti.ab.
24. exp cohort studies/
25. cohort.tw
26. exp longitudinal studies/
27. (cohort adj5 (stud$ or trial$)).tw
28. (prospectiv$ adj5 (stud$ or trial$)).tw
29. (longitudinal adj5 (stud$ or trials)).tw
30. or/18-29
31. exp Ovarian Neoplasms/
32. (ovar$ adj5 tumo?r).tw
33. (ovar$ adj5 neoplas$).tw
34. (ovar$ adj5 cancer$).tw
35. (ovar$ adj5 carcino$).tw
36. exp Adnexal Diseases/
37. exp Ovarian Cancer/
38. or/31-37
39. exp “early ovarian cancer”/
40. exp “early ovarian neoplasm”/
41. “stage I ovarian cancer”/
42. or/ 39-41




47. exp Surgical procedures, Operative/
48. or/44-47
49. 43 and 48
50. 30 and 49
See Appendix 1 for further electronic search strategies
Searching other resources
The citation list of relevant publications, abstracts of scientific
meetings and list of included studies were checked through hand
searching and experts in the field contacted to identify further re-
ports trials. The results of handsearching of the following confer-
ences/publications were searched:
Gynecologic Oncology
International Journal of Gynaecological Cancer
British Journal of Cancer
British Cancer Research Meeting
Annual Meeting of the International Gynaecologic Cancer Society
Annual Meeting of the American Society of Gynecologic Oncol-
ogist
Annual Meeting of the European Society of Medical Oncology
(ESMO)
Annual Meeting of the American Society of Clinical Oncology
(ASCO)
Data collection and analysis
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Selection of studies
All eligible studies were assessed for their methodological quality
and relevance to the review objectives. Study selection was under-
taken by the review authors. No effort was made to blind the re-
view authors for names of authors, institutions and journals. The
reason for this is that all review authors were very familiar with
the literature on early stage ovarian cancer treatment. As it was
known that no RCTs have been published, we decided to incor-
porate other types of studies in this review, i.e. cohort studies and
case-control studies, but not studies with historical controls.
Data extraction and management
All studies were assessed with the aid of a critical review form.
Three different critical review forms were used: one for RCTs
(Table 1). One for case control studies and one for cohort studies
(Table 2; Table 3, Table 4). The critical review forms were filled out
independently by the review authors to assess whether the studies
meet the inclusion criteria. Extracted data included trial character-
istics, characteristics of the study participants, interventions and
outcomes (Table 1). The quality of non RCTs were assessed us-
ing appropriate quality evaluations tools by STROBE (Strength-
ening the Reporting of Observational studies in Epidemiology)
(Vandenbroucke 2007) and Newcastle-Ottawa tool for observa-
tional studies (NOS) (Wells 2007). A“star system” has been de-
veloped in which a study was judged based on three broad per-
spectives: the selection of the study groups; the comparability of
the groups; and the ascertainment of the exposure and outcome
of interest for case control and cohort studies. The goal of this
project was to develop an instrument providing an easy and con-
venient tool for quality assessment of non randomised studies to
be included in a systematic review (Wells 2007).
Differences were resolved by discussion. When a paper contained
insufficient information to make a decision about eligibility or
when additional information was required we contacted the au-
thor/ principal investigator asking for further information.
Data synthesis
Statistical analysis was performed in accordance to the guidelines
developed by the Cochrane Gynaecological Cancer Group. All tri-
als were initially included in one analysis of surgical laparoscopy
and laparotomy for early stage ovarian cancer. However, it was im-
possible to performed the meta-analysis due the methodological
difference between the studies (design and quality of report). For
that reason we performed qualitative systematic review. We assess-
ment of the quality of each studies using NOS and STROBE. NOS
use a ‘star system‘ developed on the following broad perspectives:
the selection of the study groups; comparability of the groups; and
the ascertainment of either the exposure or outcome of interest for
case-control of cohort studies respectively. The STROBE state-
ment is a checklist of 22 items that we consider essential for good
reporting of observational studies (cohort and case-control).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The initial search identified 706 citation, of which 663 were ex-
cluded and 43 were retrieved for detailed examination. Only three
published trials met the inclusion criteria, one cohort (Tozzi 2004)
and two case-control studies (Ghezzi 2007; Hua 2005) (Figure 1).
No RCTs were identified.
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Figure 1. Study selection process
Included studies
Settings
The three included studies were of single-centre design, conducted
in Italy (Ghezzi 2007; Tozzi 2004) and China (Hua 2005) which
was translated from Chinese to Portuguese.
Designs
One case-control study compared ten consecutive patients sub-
mitted to laparoscopy for early stage ovarian cancer with eleven
patients with the same diagnosis who underwent laparotomy (Hua
2005). Another case-control study compared 15 patients with early
stage ovarian cancer submitted to laparoscopy with another group
of 19 patients with the same diagnosis submitted to laparotomy
(Ghezzi 2007).
We found one prospective cohort study with 42 patients eligible to
enter the study with ovarian cancer FIGO stage IA to IB and follow
up around 46.4 months (SD 16.25; range 2 to 72 months), initially
submitted to laparoscopy (Tozzi 2004). However, 18 patients were
excluded due to tumour rupture (n = 5) not explained if occurred
during or before surgery, presence of peritoneal implants (n = 3),
ovarian surface invasion (n = 4), or microscopic invasion at frozen
section analysis (n = 2), tumour size large than 11 x 8 cm, which
is the largest diameter of the endobag (n = 4). In these,18 cases
laparoscopy was converted to laparotomy.
Participants
All women included in the trials had malignant ovarian tumours
and underwent a preliminary workup, including ultrasonography,
CA 125, and colour Doppler ultrasonography followed by surgery
(laparoscopy or laparotomy).
In the cohort study (Tozzi 2004) 24 patients were submitted to la-
paroscopy, the median age was 36.8 years (SD 13.5, range 19 to76)
and histological results were as follows: 20.8% serous, 12.5%,
respectively, were mucinous, and dysgerminoma, 8,3% were en-
dometrioid, and 4,1%, respectively, clear cell, yolk sack tumour,
teratoma and granuloma cells. Histological grading was G1, G2
and G3, in 50%, 33% and 16,6%, respectively. Tumour stage was
50% IA, 20.8% IB and 29.2% IC. (Tozzi 2004).
Thirty-four patients with apparent early stage ovarian cancer were
submitted for surgery . In the case-control study (Ghezzi 2007)
15 patients undergoing a comprehensive laparoscopic staging were
compared with 19 patiens that were submitted to laparotomy. Age
in the laparoscopy group: 55 years (SD 13.5; range 13 to 70).
Age in the laparotomy group: 61 years (standard deviation (SD)
0.58; range 44 to 70), the body mass index 23.8 (SD 4.2) in the
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laparoscopy group and 25.8 (SD 3.1) in the laparotomy group.
The histopathologic study of the surgical specimens in the laparo-
scopic group showed: seven serous cystadenocarcinoma, three mu-
cous cystadenocarcinoma, three endometrioid tumours, one dys-
germinoma and one carcinosarcoma. Tumour was - 53.3% G2
and 46.6% G3. In the laparotomy group there were: 14 serous cys-
tadenocarcinoma , 2 mucous cystadenocarcinoma, 1 endometri-
oid tumour, 1 small cell carcinoma in a mature teratoma. Tumour
grading was 5.2% G1, 26.3 G2 and 68.4% G3. Final stage in the
laparoscopy group: Ia (n = 5); Ic (n = 6), IIIa (n = 2), IIIc (n = 2);
final stage in the laparotomic group: Ia (n = 8); Ic (n = 5), IIIa (n
= 3), IIIc (n = 3).Controls were selected from consecutive women
who underwent laparotomy for an apparent early stage ovarian
cancer between 1997 to 2003, and who met the same criteria for
eligibility as the laparoscopy group. Patients were operated in all
cases by the same surgeons, with extensive training and experi-
ence both in gynaecologic oncology and in advances laparoscopic
procedures. All patients received a single dose of prophylactic an-
tibiotic one hour prior to the intervention (ampicillin/sulbactam
1.5 g intravenously) as well as anti-thrombotic prophylaxis with
heparin(Ghezzi 2007).
In the case-control study (Hua 2005) 10 patients with early stage
ovarian cancer underwent laparoscopic surgery and 11 patients
with the same diagnosis underwent laparotomy. Age in the laparo-
tomy group:42 (SD 6). Age in laparoscopy group: 40 years (SD
8). In the laparoscopy group nine were epithelial tumour and one
was stromal; in the laparotomy group nine were epithelial and two
cases were stromal, and all cases had tumour grading G3
Interventions
In the cohort study patients in the laparoscopy group were submit-
ted to bilateral salpingo-oophorectomy with laparoscopic assisted
vaginal hysterectomy, pelvic lymphadenectomy, infrarenal para-
aortic lymphadenectomy, complete resection of the infundibu-
lopelvic-pelvic ligament, appendectomy and partial omentectomy
(Tozzi 2004). In the case-control studies, the patients in the la-
paroscopy group were submitted to bilateral salpingo-oophorec-
tomy with laparoscopic assisted vaginal hysterectomy, pelvic lym-
phadenectomy, infrarenal para-aortic lymphadenectomy, com-
plete resection of the infundibulopelvic-pelvic ligament, appen-
dectomy and partial omentectomy; in the laparotomy group the
patients were submitted the same procedures (Hua 2005, Ghezzi
2007). Frozen section analysis was performed in all included stud-
ies.
Outcomes
In the cohort study: survival at five years, PFS at five years, intraop-
erative complications, blood transfusions, operative time for com-
pleteness of staging and primary surgery, number of pelvic lymph
nodes resected, presence of trocar site metastasis (Tozzi 2004).
In the case control study: survival, PFS at five years, operative time,
intraoperative blood loss, intraoperative complications, number
of pelvic lymph nodes resected, (Hua 2005; Ghezzi 2007).
Excluded studies
Please see Characteristics of excluded studies. Thirty nine studies
were excluded often for more than one reason. The most common
causes for exclusion were design other than a RCT, a narrative
review, a series of cases or a retrospective studies.
Risk of bias in included studies
Inter-rater agreement for quality assessment was good (Cohen’s
kappa = 0.78). Initial disagreements were solved through discus-
sion in all cases. The quality of non-RCTs was assessed using ap-
propriate quality evaluations tools by NOS (Wells 2007) (Table 2
and Table 3) and by STROBE (Vandenbroucke 2007) (Table 4)
Cases control studies (Hua 2005, Ghezzi 2007)
(Newcastle-Ottawa)
Selection
(a) Is the case definition adequate? Yes,with independent validation
= yes*
(b) Representative of the cases: consecutives series of cases = yes*
(c) Selection controls: hospital control with the same disease
(d) Definition of controls: history of disease with the same diag-
nosis that in the laparoscopy group (treatment) = yes*
Comparability
(a) controls for early stage ovarian cancer treated by laparoscopy
or laparotomy the most important factor was selected (survival) =
Yes* for Ghezzi 2007, and no for Hua 2005
(b) controls for any additional factor (surgery complications, op-
erative time, blood transfusion, number of pelvic lymph nodes
resected, trocar site metastasis, recurrence) = yes*
Exposure
(a) Assessment of outcome: secure record (surgical records)=yes*
(b) Same method of ascertainment for cases and controls=yes*
(c) Non-response rate: rate different and no designation
We found six stars in the two case-control studies. The studies
have good quality assessment by NOS (Table 2)
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Cohort study (Tozzi 2004) (Newcastle- Ottawa)
Selection
(a) Representative of the exposed cohort: the population repre-
sented the average patients with early stage ovarian cancer de-
scribed in the community = yes*.
(b) Draw from the same community as the exposed cohort = yes*
(c) Ascertainment of exposure: surgical records = yes*
(d) Demonstration that the outcome of interest was not present
at the start of the study = yes*
Comparability
(a) Controls for early stage ovarian cancer treated by laparoscopy
or laparotomy - the most important factor was select (survival)=
yes*
(b) Controls for any additional factor (surgery complications, op-
erative time, blood transfusion, number of pelvic lymph nodes
resected, trocar metastasis, recurrence)=yes*
Outcomes
(a) Assessment of outcome: record linkage = yes*
(b) Was the follow up long enough for the occurrence of outcomes?
yes (46,4 months) = yes*
(c) Subjects lost from follow up unlikely to introduce bias - small
number lost > 100% (selected and adequate%) follow up, or de-
scription provide of those lost = yes*
We found nine stars in the cohort study, the corresponding to an
excellent quality by NOS (Table 3).
Evaluation of quality by STROBE (Vandenbroucke
2007) of three included studies
From a checklist of 22 items, all three studies showed problems
with seven items: title, variables, bias, statistical methods, par-
ticipants, main results and other analysis (Table 4). The studies
(Ghezzi 2007;.Hua 2005; Tozzi 2004) did not give information
about potential confounders and effects modifiers (item 7) and
did not describe potential sources of bias (item 9). In the statistical
methods there was no description for the control of confounding
factors and, the subgroups and interactions were not described in
the sensitivity analysis (item 12). In the results there was no con-
sideration for the use of a flow diagram (item 13). In the main
results unadjusted estimates were not given and, when applica-
ble, confounder-adjusted estimate and their precision were not
describe (e.g., 95% confidence intervals [CI]) (item 16). There
was no reported on subgroup analysis, interactions and sensitivity
analysis (item 17). When describing the limitations of the studies
was no description of sources, directions and magnitude of poten-
tial bias. Conclusion: there were problems in important items in
the STROBE, for considering a study of good quality.
Effects of interventions
A meta-analysis was not possible due to differences among studies
and because STROBE has a low quality for evaluations of impor-
tant outcomes. Therefore, we performed a qualitative systematic
review. We used three selected observational studies ( two case-
control and one cohort study) (Ghezzi 2007; Hua 2005; Tozzi
2004). These three studies met the inclusion criteria with a total
97 patients with early stage ovarian cancer.
Cohort Study
(Tozzi 2004). Forty-two patients were eligible for the study and
were submitted to laparoscopy. In 18 of these patients there were
conversion to laparotomy due to tumour rupture in 5 cases, peri-
toneal implants in 3 cases, ovarian surface invasion in 4 cases,
and microscopic invasion at frozen section analysis was in 2 cases,
and large tumour size in 4 cases. Tozzi 2004 describe only the
laparoscopy group.
Primary outcomes
Survival at five years
In Tozzi 2004 the survival for 24 patients at maximum follow up
72 months (median 46.6, SD 16.25; range 2 to 72 months) and
OS was 100%.
PFS at five years
In Tozzi 2004 two patients (8.3%) had tumour recurrence in the
laparoscopy group. One patient, primarily treated with surgery
and chemotherapy for an epithelial ovarian cancer FIGO IB G3,
had a pelvic recurrence and underwent secondary surgery with
debulking and bowel resection followed by second-line chemo-
therapy. The second patient with a diagnosis of epithelial ovarian
cancer FIGO IA G3 received six cycles of platinum and paclitaxel
because of positive peritoneal biopsies at second-look laparoscopy.
Disease-free survival was 91.6% in 24 cases.
Secondary outcomes
(1) Tumour spillage at the time of surgery : from 42 eligible patients
tumour spillage occurred in 5 (11.9).
(2) Local recurrence: for the laparoscopy (porte-site) and laparo-
tomy (midline incision) groups: until 2004 there was no trocar site
metastasis in 24 cases. In 15 out of 24 patients (62.5%) a second-
look laparoscopy was performed, and local recurrence occurred in
1 case.
(3) Distant recurrence: until 2004 there were no distant recur-
rences, there were two pelvic recurrences out of 24 cases.
(4) Surgical outcome
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(a) Complications (immediate and delayed):
(i) Injury (bladder, urether, vascular, small bowel and colon in-
juries): did not occur.
(ii) Presence /complications and adhesions: not described.
(iii) Fever: not described.
(iv) Intestinal obstruction: did not occur.
(v) Haematoma: did not occur.
(vi) Infection: not described.
(vii) Convertion to laparotomy: from 42 patients initially eligible
to laparoscopy, 18 were submitted to a laparotomy (42.8%).
(vii) Systemic complications: one patient developed chylous ascites
with spontaneous evacuation of the lymphatic fluid through ab-
dominal drainage, the patient was discharged 12 days after surgery.
There were no cases of chest infection, deep venous thrombosis,
pulmonary embolism, cardiac failure, cardiac ischemias or cere-
brovascular accident.
(B) Operative time: mean operative time for all patients was 176
min (SD 48.45; range:102 to 306 min); it a took a mean of 166
min (SD 20.9 range 118 to 206 min) for complete stating and
182 (SD 39.18 ; range 141 to 306) for the primary treatment
of patients who underwent LAVH (laparoscopy assisted vaginal
hysterectomy) with contralateral salpingo-oophorectomy.
(c) Recovery from surgery:
(i) length of hospital stay: The overall mean length of hospital
stay was 7 days (SD 1.66; range 5 to12). Adjuvant treatment was
proposed in five cases.
(ii) re-admission rates: not described.
(d) Mean number of bilateral pelvic lymph nodes:19,6 (SD 7.1; range
5 to 35).
Case Control
(Hua 2005). Ten patients with early stage ovarian cancer were
submitted to laparoscopic total hysterectomy, pelvic lymph nodes
dissection, bilateral adnexectomy, high ligation of the ovarian aor-
tic and vein, omentectomy, and additional appendectomy. Eleven
patients with the same diagnosis underwent the same procedure
by laparotomy.
Primary outcomes
1) Survival at five years: not reported
(2) PFS at five years : not reported
Secondary outcomes
(1) Tumour spillage at time of surgery:
Laparoscopy: yes, all cases by vaginal puncture ovarian tumour
Laparotomy : not reported.








(a) Complications (immediate and delayed):
(i) Injury (bladder, urether, vascular, small bowel and colon in-
juries):
Laparoscopy: The right obturator nerve was injured and was su-
tured.
Laparotomy: did not occur.
(ii) Presence /complications and adhesions:
Laparoscopy: right obturator nerve was injured.






Laparoscopy: did not occur.






Laparotomy: one case of wound infection.
(vii) Conversention to laparotomy: did not occur.
(vii) Systemic complications:
Laparoscopy: did not occur.
Laparotomy: did not occur.
(viii) Blood loss
Laparoscopy: 280 ml (SD 156 ml),
Laparotomy: 346 ml (SD 170 ml).There were statistically signifi-
cantly differences in blood loss between the two groups (p < 0.05).
(b) Operative time:
Laparoscopy: 298 min (SD 60 min)
Laparotomy: 182 min (SD 43 min). There were statistically sig-
nificantly differences the two groups (p < 0.05)
(c) recovery from surgery:
(i) length of hospital stay:
Laparoscopy: not reported.
Laparotomy: not reported.
(ii) re admissions rate:
Laparoscopy:not reported.
Laparotomy:not reported.
(d) Mean number of bilateral pelvic lymph nodes
Laparoscopy : 25 (SD 5)
Laparotomy: 27 (SD 7).There were no statistically significantly
differences between the two groups (p > 0.05)
Case Control
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(Ghezzi 2007). Fifeteen patients with early stage ovarian cancer
were submitted to laparoscopic total hysterectomy, pelvic lymph
nodes dissection, bilateral adnexectomy, high ligation of the ovar-
ian aortic and vein, omentectomy, and additional appendectomy.
Nineteen patients with the same diagnosis who underwent the
same procedure by laparotomy served as a control group.
Primary outcomes
1) Survival at five years : The laparoscopy group had at least two
years of follow up with 100% survival. For the laparotomy group
survival was also 100%, but the follow up time had a median of
29 months (SD 18,5; range 14 to 92).
(2) PFS at five years: in the laparoscopy group there were no re-
currences and in the laparotomy group there were 4 recurrences
(7.1%).
Secondary outcomes
(1) Tumour spillage at the time of surgery:
Laparoscopy: in three cases.
Laparotomy : in two cases.








(a) Complications (immediate and delayed):














Laparoscopy: retroperitoneal haematoma requiring laparotomy
and hypogastric arteries ligature occurred 7 h after surgery.
Laparotomy: there were no haematomas.
(vi) Infection:
Laparoscopy: not reported.
Laparotomy: 6 cases: urinary infection (n = 4) and wound infection
(n = 2).





Laparoscopy: 250 ml (SD 225; range 50 to 1000) in one patient
who had a retroperitoneal haematoma and had to received six units
of packed red blood cells plus four units of fresh frozen blood.
Laparotomy: 400 ml (SD 201; range 150 to 1000). Not significant.
(B) Operative time:
Laparoscopy: 377 min (SD 47 min)
Laparotomy: 272 min (SD 81 min). There were statistically sig-
nificance differences between two groups (P < 0.05).
(C) recovery from surgery:
(i) length of hospital stay:
Laparoscopy : 3 days (SD 2.3; range 2 to 12).
Laparotomy: 7 days (SD 2.3; range 4 to 14). There were statistically




(d) Mean number of bilateral pelvic lymph nodes
Laparoscopy : 25.2 (SD 9.3)
Laparotomy: 25.1(SD 5.8).There were no statistically significant
differences between the two groups (p >0.05).
D I S C U S S I O N
The challenge when trying to conduct a systematic review on sur-
gical management by laparoscopy or laparotomy in patients with
early stage ovarian cancer is that this a rare disease. It is not re-
alistic to expect a large number of RCTs. We found only three
observational studies with good quality by Newcastle- Ottawa
tool (Wells 2007), although they had important problems in the
STROBE checklist (Vandenbroucke 2007). Good reporting re-
veals the strengths and weaknesses of a study and facilitates inter-
pretations and applications of the results. In this systematic review
a meta-analysis was not possible due to differences in the quality
among studies. Therefore we performed a qualitative systematic
review. Egger et al. showed that meta-analysis of observational data
may produce precise but spurious results. The statistical combi-
nation of data should therefore not be an important component
of systematic reviews of observational studies (Egger 2001). How-
ever, clinical decisions may still be made on the basis of evidence
derived from non-randomised observational studies, such as co-
hort and case-control studies. Although observational studies may
provide useful results, they are limited due to unrecognised con-
founding factors, which may distort results (bias). Concato et al.,
showed that results of well-designed observational studies do not
overestimate the magnitude of the effects of treatments systemat-
11Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ically as compared to results from randomised controlled trials on
the same topic (Concato 2000).
Controversy has arisen between endoscopists and oncologists
about the laparoscopic management of early stage ovarian tu-
mours. Kinderman et al. wrote that 39% of the stage Ia ovarian
cancer may spread after endoscopic procedures, demonstrating
implant and metastases, even in an early follow up phase. It was
harmful for the majority of patients when the subsequent laparo-
tomy indicated due to very early implants and metastases in the
pelvis, in the abdominal cavity or in the laparoscopic trocar site
was delayed for more than eight days after the endoscopic proce-
dure (Kindermann 1995). For Ramirez et al., laparoscopic port-
site metastases are a potential complications of laparoscopy in pa-
tients with gynaecological cancer (Ramirez 2004). Gleeson et al.,
Childers et al., Leminen et al. and Kadar et al., reported cases of
abdominal wall metastases from ovarian cancer after laparoscopy
(Childers 1994; Gleeson 1993; Leminen 1999). Romagnolo et al.,
described tumour rupture or spilling during surgery, with a statis-
cally significant greater incidence in the group of patients treated
by laparoscopy (34.6%) when compared to laparotomy (6.6%), p
< 0.0001 (Romagnolo 2006). Dembo et al., performed a multi-
variable analysis by Cox Regression for survival analysis and found
the following prognostic factors: grade, adherences and ascites. In
their analysis capsular rupture, stages Ia, Ib, size and age were not
significant factors for survival (Dembo 1990). In addition Sjövall
et al. did not find differences in survival between patiens whose
tumours had intact capsules and those in whom rupture occurred
during surgery (78 and 85%, respectively). However, when the
rupture occurred before surgery survival was only 59%. (Sjövall
1994). Volz et al., analysed animal models microscopically and
showed, that induction of a pneumoperitoneum caused diffuse
damage to the entire mesothelial cell layer with exposure of the
basal lamina and development of extensive mechanisms of re-
pair. The exposure of the extracellular matrix proteins including
laminin, fibronectin, and vitronectin to the tumour cell surface is a
possible mechanism for increased tumour cell adherence. A second
mechanism may be the promotion of intraperitoneal tumour cell
growth by increased interleukin 1 production by the peritoneal
macrophages, which are extensively involved in this unique repair
mechanism (Volz 1999).
The guidelines for epithelial ovarian carcinoma FIGO stage I in-
clude both surgical and adjuvant therapeutic procedures (Sijmons
2007). Recently two parallel RCTs, ICON1 and ACTION tri-
als showed in that adjuvant chemotherapy would provide further
benefits for women with stage I ovarian cancer (Trimbos 2003).
There are still no consensus on how to separate patients with sur-
gical stage I disease who are at a higher risk of tumour recurrence
and death from those with a low risk. Histological grade is consid-
ered one the most important prognostic factors in stage I epithelial
ovarian cancer (Vergote 2001).Tumour rupture, capsular penetra-
tion and dense adhesions are generally believed to be associated
with worse prognosis in these cases (Vergote 2001). Obermair et
al, analysed 456 patients, with Grade 3 stage I ovarian cancer and
found an, OS in five years of 87 % (95% CI 80.3 to 93.6); if CA
125 was higher than 30 U/ml OS in five years was 86% (95% CI
81.8 to 90.9) (Obermair 2007). In the staging ovarian cancer mi-
croscopic assessment of grade provide a better discriminations for
the necessity of further interventions than blind biopsies. Grade
and ploidy may be surrogates for genetic instability, which may
be the principal determinant of prognosis. With the publication
of the ICON 1 and ACTION trials plus other evidences in the
literature in last few years, tumoral grade achieved the power to
determine adjuvant treatment in early stage ovarian cancer and
should now be incorporate to stage for treatment decisions(Green
2003).
In this systematic review, the cohort study showed out of 100%
with 2 recurrences, and a follow up ranging 2 to 72 months;
42.2% were eligible initially to laparoscopy but had conversion to
laparotomy. The operative time was 176 min (SD 20.9) in the la-
paroscopy group (Tozzi 2004). In case-control studies, Hua et al.,
showed an operative time for the laparoscopy group of 298 min
(SD 60 min) and Ghezzi et al., found an time of 377 min (SD 47
min). In vitro, the ovarian carcinomatous cells exposed to carbon
dioxide for 3 hours had a 52% increase in growth by 4 days after
exposure. This increased cell growth had a linear relationship with
the length of exposure to carbon dioxide when compared to now-
exposed control cells (Smidt 2001). Three major pathways exist
for the dissemination of ovarian malignancies: via bloodstream, via
lymphatic channels, and spread through the abdomen and pelvis
as a result of rupture of the ovarian capsule (Sugarbaker 1996). For
Greene et al., the mechanical effect of pneumoperitoneum and
the probable result of the pressure may cause cellular dissemina-
tion. The effects of this mechanical dissemination in an already
immunocompromised host sets up an ideal mechanism for growth
that may be observed early in the postoperative evaluation of the
violated abdominal wall (Greene 1995).
On the other hand, there are a number of reports in the literature
describing the use of operative laparoscopy in patients with early
stage ovarian cancer (Childers 1994). Pelvic and para-aortic la-
paroscopic lymphadenectomy, appear to be feasible and adequate,
although there may occur a mechanical effect caused by the pneu-
moperitoneum damage in the mesothelial cell layer. According
to the FIGO, the prognosis of all ovarian tumours are indepen-
dently affected by the following factors: stage of cancer at diagno-
sis, histological subtype grade and volume of residual disease after
surgery (Benedet 2000). Therefore, the staging laparotomy is the
most important part of the early management of ovarian tumours.
Benedet et al, showed that laparoscopy is more appropriate if the
suspicion favours a benign diagnosis in a young woman with nor-
mal levels of tumoral (Benedet 2000). Canis et al. showed that the
incidence of spread of ovarian cancer after laparoscopy surgery is
difficult to establish and the prognostic relevance trocar site metas-
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tasis is not known (Canis 2001). The authors concluded that the
laparoscopic management of ovarian cancer remains controversial
and that; it should be performed only in prospective clinical trials
(Canis 2001). Until the results of such studies become available,
an immediate vertical midline laparotomy remains the gold stan-
dard if a malignant tumour is found (Canis 2001).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
According to FIGO the primary surgery for patients with early
stage ovarian cancer should be a vertical abdominal incision, with
sampling from the peritoneal fluid and the entire peritoneal sur-
face of the abdominopelvic wall; inspection and palpation of the
cavity from the pelvis to the diaphragm is recommended in the
search for tumoral implants (Benedet 2000). We did not find any
good evidence for the recommendation of laparoscopy for the rou-
tine management of patients with early stage ovarian cancer. This
review does not support the use of laparoscopy in the routine prac-
tice for the management early stage ovarian cancer.
Implications for research
Further trials should carefully address the methods of randomi-
sation as blinding is impractical in these kind of studies. Future
research should include specific patient subgroups and include
additional outcomes such as surgical efficacy, tumour recurrence,
patient satisfaction, quality of life, costs, survival at five years and
PFS at five years. The follow up period should provide more in-
formation on recurrence, and on the potentially harmful effects
of laparoscopy. For evaluation of costs it would be helpful if it
were reported separately for the preoperative, intraoperative and
postoperative periods.
Survival data for patients with gynaecologic malignancies managed
by laparoscopy are still lacking. It is imperative that the survival is
not compromised by employing new surgical techniques.
These and other important issues should be addressed by future
trials before the role of laparoscopy in gynaecological oncology
can be determined.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ghezzi 2007
Methods Case and control study.
No Data on sample size calculation and power.
The study was carried in 2003 in Department of Obstetrics and Gynecology, University of Insubria,
Del Ponto Hospital, Piazza Biroldim I, Vareses , Italy and in Department of Obstetrics and Gynecology,
University of Verona, Italy
Participants 34 patients with apparent early ovarian cancer was submitted for surgery . 15 patients undergoing a
comprehensive laparoscopic stating and were compared with 19 patients that were submitted for laparo-
tomy. All women were submitted for preliminary workup, including ultrasonography, CA 125, as well as
colour Doppler ultrasonography. Age (years) in the laparoscopy group: 55 years (SD 13.5; range 13-70).
Age (years) in the laparotomy group: 61 (SD 0.58; range 44-70), body mass index 23.8 (SD 4.2) in the
laparoscopy group and 25.8 (SD 3.1)
Interventions Laparoscopic and laparotomy for treatment early ovarian cancer. Intraoperative mass rupture was defined
as any rupture, intentional, or unintentional, that results in spill of cysts contents into the peritoneal cavity.
retrieved via an endobag to avoid contact with the port sites and submitted for frozen section. After the
diagnosis of malignancy, multiple random peritoneal were performed. Bilateral lymphadenectomy was
performed as previously described and all patients, external iliac, internal iliac and obturator lymphonodes
were removed. Common iliac and paraarortic lymphadenectomy were performed. Total infracolic omen-
tectomy was than performed using scissors and bipolar coagulation. Appendicectomy were performed.
Salpingo-oophorectomy and total laparoscopic hysterectomy were performed
Outcomes Postoperative complications were defined as adverse events occuring within 30 days of surgery as a result
of the procedure. Febrile morbidity was defined two temperatures > 38, hospital stay, blood loss, blood
transfusions, pelvic lymph nodes, paraaortic lymphnodes
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Hua 2005
Methods Case and control study.
The study was carried out between September 2002 to may 2004 in Department of Gynecology, Fudan
University, Gynecology and Obstetric Hospital, Shangai 200011, China
Participants 21 patients with early ovarian cancer were evaluated. 10 were submitted the laparoscopic operation and
11 were submitted the laparotomy.
Mean age in laparoscopy group was 40 (SD8). Mean age in laparotomy group was 42 (SD6)
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Hua 2005 (Continued)
Interventions Laparoscopic in 10 patients with early ovarian cancer who underwent laparoscopic total hysterectomy,
pelvic lymph nodes dissection, bilateral adnexectomy, ovarian aortic and vein high ligation, omentectomy,
and additional appendicectomy
Laparatomy in 11 patients with early ovarian cancer who underwent the same procedure.
Frozen section method during operation proved the diagnosis of ovarian cancer and cytological examina-
tion proved negative result of the peritoneal irrigation liquid
Outcomes Operative time, intraoperative blood loss, number of pelvic lymph node resected, surgical complications
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Tozzi 2004
Methods Cohort prospective.
No data on sample size calculation and power and precision.
The study was carried out between May 1996 until June 2003 in Departament of Gynecology, Friedrich
Shiller, Jena, Germany
Participants Forty two patients were eligible to enter the study, but 18 patients were excluded because of tumor rupture
(n=5), presence of peritoneal tumor implants (n=3), ovarian surface invasion either macroscopic (n=4), or
microscopic at frozen (n=2) or because of tumor size (n=4), exceeding 11 x 8 cm , which is the diameter of
biggest endobag. All these conditions managed conversion to laparotomy. Thus, 24 patients with FIGO
stage IA-B underwent either primary treatment or completation of staging by laparoscopy. All women
were submitted a preliminary workup, including ultrasonography, CA 125, as well as colour Doppler
ultrasonography. Age (years) in the laparoscopy group: 36.8 (SD 13.5; range 19-76) and body mass index
27.3 (SD 4.37; 20.2-38.6).
I
Interventions 24 patients with ovarian FIGO stage IA-B were managed by laparoscopy. All patients underwent bowel
preparation. The procedure was started by laparoscopy with peritoneal washing and careful inspection of
the entire abdomen including diaphragm, liver, gallbladder, small bowel, reto-sigmoide colon, paracolic
gutter and abdominal wall. Any suspicious lesion was biopsied and sent for frozen section. All specimens
were retrieved via endobag to avoid contents with port site. If necessary, puncture and drainage were
performed in the endobag. The integrity of endobag was checked after extraction from the abdomen and
the tumor was sent frozen section.
Once the diagnosis of cancer was confirmed, intraperitoneal spread was excluded by laparoscopy and
tumor rupture avoided and laparoscopic assisted vaginal hysterectomy (LAVH) with contralateral salpingo-
oophorectomy, appendectomy, partial resection of the omentum, pelvic lymphadenectomy and infrarenal
para aortic bilateral lymphadenectomy. Also appendectomy was performed
Outcomes Operative complications, surgery time, mean number of pelvic lymph nodes, hospital stay, survival and
PFS at five years
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Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amara 1996 Series of cases.
Berman 2003 Narrative review.
Bristow 2000 Narrative review.
Canis 1994 Narrative review.
Canis 1997 Not give the stage of ovarian cancer (Ia, Ib or Ic). They wrote about 10 cases of low malignant potential tumour
and 15 cases of cancer, but without stage
Canis 2000 Not give the stage of ovarian cancer (Ia, Ib or Ic). Only related about 28 cases of cancer and borderline tumor
Chapron 1998 Narrative review.
Childers 1995 Case control trial, but with second look laparoscopy to evaluate both intraperitoneal cavity and retroperitoneal
lymph nodes
Childers 1996 The stage of ovarian cancer (Ia, Ib or Ic) not given. Only related about 19 cases of cancer
Darai1998 Retrospective trial.
Dottino 1999 Another ovarian disease, wrote about ovarian cancer, they gave stage IIC, IIIa abd IV for ovarian cancer
Fauvet 2005 Retrospective study.
Goff 2006 Narrative review.
Kadar 1995 Not randomised. Other kind of cancer (endometrial, cervical, ovarian)
Klindermann 1995 A questionnaire was mailed to 237 German Department Gyn/obs. A response rate 46% (127 hospital) con-
cerning the Endoscopicall technique used for cancer operation
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(Continued)
Leblanc 2004 Cohort with other types of cancer (fallopian tube carcinoma), and in patients that were inadequately staged at
the time of initial surgery for invasive ovarian carcinoma
Leblanc 2006 Narrative review.
Lécuru 2004 Retrospective and multi centric study.
Maiman 1991 Members and candidate members of the Society of Gynecologic Oncologists responded to a survey concerning
the “laparoscopy management of ovarian neoplasm subsequently found be malignant”
Malik 1998 Retrospective study.
Maneo 2004 Criteria of exclusion: 62 patients had fertility -sparing after surgery
Manolitsas 2001 Narrative review.
Mehra 2004 To describe experience of laparoscopy extraperitoneal paraaortic in 32 patients with cervical, ovarian and
endometrial carcinomas
Nezhat 1992 Series cases.
Parker 1990 Only benign ovarian cysts.
Pomel 1995 Patients with I ovarian carcinoma underwent a laparoscopic procedure to complete their staging
Poncheville 2001 Retrospective study.
Querleu 2003 Retrospective study.
Querleu 2006 Many types of tumors (cervical, vaginal, endometrial, and ovarian carcinoma)
Querleu 2006 Narrartive review.
Reich 1990 Series of cases.
Romagnolo 2006 Patients affected by ovarian mass suspected of borderline ovarian tumor are operated - primary laparoscopic,
but 46.9% have no for exclusion of SR, because a fertility-sparing surgical treatment was chosen
Rouzier 2005 Narrative review.
Spirtos 2005 Other kinds of gynecological cancer.
Tozzi 2005 Narrative review.
Tropé 2006 Narrative review.
Vaisbuch 2005 Narrative review.
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(Continued)
Vergote 2003 Narrative review.
Vinatier 1996 Narrative review.
Volz 1996 Narrative Review.
Wenzl 1996 A questionnaire was sent to all 97 Departaments of Gynecology in Austria was to determine the frequency of
discovering a malignant ovarian mass when laparoscopy is uses to manage an adnexal mass
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Newastle-Ottawa Quality Assessment Scale Case Control Study
Numbered item Hua 2005 Ghezzi 2007
SELECTION
1) Is the case definition adequate?
(a) Yes, with independent validation?* Yes* Yes*
(b) Yes, e.g., record linkage or based on self
reports
(c) No description
2) Representativeness of the cases
(a) Consecutive or obviously representative
series of cases*
Yes* Yes*
(b) Potential for selection biases or not
stated
3) Selection of Controls
(a) Community controls *
(b) Hospital controls Yes Yes
(c) No description
4) Definition of controls
(a) No history of disease (endpoint)* Yes* Yes*
(b) No description of source
COMPARABILITY
1) Comparability of cases and controls on
the basis of design or analysis
(a) Study controls for selected the most
important factor.*
Yes* Yes*
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Table 1. Newastle-Ottawa Quality Assessment Scale Case Control Study (Continued)
(b) Study controls for any additional factor
* (This criteria could be modified to indi-




1) Ascertaiment of exposure
(a) Secure record (e.g., surgical records) * Yes* Yes*
(b) Strutured interview where blind to case/
control status*
(c) Interview not blinded to case/controls
status
(d) Written self report or medical record
only
(e) No description
2) Same method of ascertainment for cases
and controls
(a) Yes *
(b) No No no
3) Non-response rate
(a) Same rate for both groups* No No
(b) No respondents described ------- --------
(c) Rate different and no designation Yes Yes
Table 2. Newastle-Ottawa Quality Assessment Scale Cohort Study
Numbered item Tozzi 2007
SELECTION
1) Representative of the exposed cohort
(a) Truly representative of the average
(describe) in the community.*
Yes*
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Table 2. Newastle-Ottawa Quality Assessment Scale Cohort Study (Continued)
(b) Somewhat representative of average
in the community*
(c) Select group of users e.g., nurses, volunteers
(d) No description of the derivation of the cohort
2) Selection of the non exposed cohort
(a)Drawn from the same community as the exposed cohort * Yes*
(b) Drawn from a different source
(c) No description of the derivation of the non exposed cohort
3) Ascertainment of exposure
(a) Secure record (e.g., surgical records) * Yes*
(b) Strutured interview*
(c) Writen self report
(d) No description
4) Demonstration that outcome of interest was not present as start
of study
(a) Yes * Yes*
(b) No
COMPARABILITY
1) Comparability of cohorts on the basis of design or analysis
(a) Study controls for (selected the most important factor)
*
Yes*
(b) Study controls for any additional factor * (This criteria could




1) Assessment of outcome
(a) Independently blind assessment *
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Table 2. Newastle-Ottawa Quality Assessment Scale Cohort Study (Continued)
(b) Record linage * Yes*
(c) self report
(d) no description
2) Was follow up enough for outcomes to occur




3) Adequacy of follow up of cohorts
(a) Complete follow up - all subjects accounted for * Yes*
(b) Subjects lost to follow up unlikely to introduce bias - small
number lost > % (select an adequate%) follow up, or descrip-
tion provide of those lost *
(c) Follow up rate < % (selected an adequante %) and no
description of those lost
(d) No statement
Table 3. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
Item Item number Recomendations Guezzi 2007 Hua 2005 Tozzi 2004
Title and Abstract 1 (a) indicate the
study’s design with a
commonly used term
in the title or the ab-
stract
No No No
(b) provide in the ab-
stract and informa-
tive and balaced sum-
mary of what was





2 Explain the scientific
background and ra-
tionale for the in-
vestigations being re-
Yes Yes Yes
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Table 3. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (Continued)
ported






Study design 4 Present key elements
of study design early
in paper.
Yes Yes Yes







Participants 6 (a)Cohort study: give
eligi-
bility criteria, and the
sources and methods
of selection or partici-




trol study: give the el-
igibility criteria, and
the sources and meth-
ods of case ascertai-
ment and control se-
lection
Yes Yes








8 For each variable of
interest, give sources
of data and details
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Table 3. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (Continued)
sessment methods if
there is more than one
group. Give such in-
formation separately
for cases and controls
studies, and, if appli-
cable, for exposed and
unexposed groups in
cohort and cross sec-
tional studies




Study Size 10 Explain how the





11 Explain how quanti-
tative variables were
handled in the analy-
sis. If applicable, de-
scribe which group-
ings were chosen and
why
Yes Yes Yes
Statistical Methods 12 (a) Describe all sta-
tistical methods, in-









(c) Explain how miss-
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Table 3. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (Continued)
of cases and controls
was adderessed





13* (a) report the number
of individuals at each



















cases and controls in
case control studies,
if applicable, for ex-
posed and unexposed





14* (a) give characteris-




on exposures and po-
tential confounders/
Yes Yes Yes
(b) indicate the num-
ber of participants
with missing data for
each variable of inter-
est
No No No
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Table 3. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (Continued)
(c) Co-
hort study: summa-
rize follow up time -





cases and controls in
case control studies,
if applicable, for ex-
posed and unexposed



















cases and controls in
case control studies,
if applicable, for ex-
posed and unexposed





16 (a) give unadjusted






. Make clear which
confounders were ad-
justed for and why
they were included
No No No
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(c) If relevant, con-
sider translating esti-
mates or relative risk
into absolute risk for





17 Report other analysis






Key results 18 Summarize key re-
sults with reference to
study objectives
Yes Yes Yes
Limitations 19 Discuss limitations of
the study , talking
into account sources
of potential bias or
impression. Discuss
both directions and
magnitude of any po-
tential bias
No No No






sis, results from simi-
lar studies, and other
relevant evidence
Yes Yes Yes
Generalization 21 Discuss the general-
ization (external va-
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Table 3. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (Continued)
Funding 22 Give
the source of funding
and the role of fun-
ders for the present
study and, if appli-
cable, for the origi-
nal study on which
the present article is
based
Yes Yes Yes










Operative time 298 min (SD 60
min)
182 min (SD 43
min)
<0.05 377 min (SD 47
min)
272 min (SD 81
min)
0.002
Blood loss (ml) 280 ml (SD 280
ml)










25 (SD 5) 27 ( SD 7) >0,05 25.2 (SD 9.3) 25.1 (SD 5.8) >0.05
Post-operative
complications
2 (20%) 7 (72.7%) 0,05 2 (13.3%) 8 (42.1%) 0.13
Number of pa-
tients
10 11 15 19
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A P P E N D I C E S
Appendix 1. Electronic search strategies
EMBASE was searched using the following strategies:
1. Controlled study/or Randomized Controlled trial/
2. double blind procedure/









12. ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw,tn,mf.
13. (comparative adj5 trial$).ti,ab,hw,tn,mf.
14. (clinical adj5 trial$).ti,ab,hw,tn,mf.
15. or/ 1-14
16. nonhuman/
17. (animal not human)/
18. or/16-17
19. 15 not 18
20. comparative study.ti,ab,hw,tn,mf.
21. follow up studies.ti,ab,hw,tn,mf.
22. prospective studies.ti,ab,hw,tn,mf.




27. (cohort adj5 trial$).ti,ab,hw,tn,mf.
28. (prospectiv$ adj5 trial$).ab,hw,tn,mf.
29. (longitudinal adj5 trials).ti,ab,hw,tn,mf.
30. or/19-29
31. exp Ovarian Neoplasms/
32. (ovar$ adj5 tumo?r).tw
33. (ovar$ adj5 neoplas$).tw
34. (ovar$ adj5 cancer$).tw
35. (ovar$ adj5 carcino$).tw
36. exp Adnexal Diseases/
37. exp Ovarian Cancer/
38. or/ 31-37
39. exp “early ovarian cancer”/
40. exp “early ovarian neoplasm”/
41. “stage I ovarian cancer”/
42. or/39-41




47. exp Surgical Technique
48. or/43-46
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49. 43 and 48
50. 30 and 49
CENTRAL (Issue 2, 2007) The Cochrane Library, the National Research Register (NRR) and Clinical Trials Register were also searched
in all fields using the following words: ovarian cancer, laparotomy, laparoscopy, ovarian surgery.
W H A T ’ S N E W
Last assessed as up-to-date: 20 July 2008.
Date Event Description
9 November 2010 Amended Author contact details amended
14 May 2008 Amended Converted to new review format.
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